These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18832042)

  • 1. Improvement of microcirculation after percutaneous transluminal angioplasty in the lower limb with prostaglandin E1.
    Heider P; Wildgruber M; Wolf O; Schuster T; Lutzenberger W; Berger H; Eckstein HH
    Prostaglandins Other Lipid Mediat; 2009 Jan; 88(1-2):23-30. PubMed ID: 18832042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcutaneous oximetry compared to ankle-brachial-index measurement in the evaluation of percutaneous transluminal angioplasty.
    Wildgruber M; Wolf O; Weiss W; Berger H; Lutzenberger W; Eckstein HH; Heider P
    Eur J Radiol; 2007 Nov; 64(2):302-8. PubMed ID: 17386992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
    Thum J; Caspary L; Creutzig A; Alexander K
    Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midterm results of prostaglandin E1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication.
    Nakanishi K; Tanaka M; Misawa H; Takigawa T; Ozaki T
    Spine (Phila Pa 1976); 2008 Jun; 33(13):1465-9. PubMed ID: 18520942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does percutaneous transluminal angioplasty improve quality of life?
    Keeling AN; Naughton PA; O'Connell A; Lee MJ
    J Vasc Interv Radiol; 2008 Feb; 19(2 Pt 1):169-76. PubMed ID: 18341944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
    Matsui K; Ikeda U; Murakami Y; Yoshioka T; Shimada K
    Am Heart J; 2003 Feb; 145(2):330-3. PubMed ID: 12595852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PGE1).
    Scheffler P; Gross J; Markwirth T; Maier J; Schieffer H
    Eur J Clin Pharmacol; 1996; 51(3-4):235-9. PubMed ID: 9010691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia.
    Schellong S; Altmann E; von Bilderling P; Rudofsky G; Waldhausen P; Rogatti W
    Prostaglandins Leukot Essent Fatty Acids; 2004 Jun; 70(6):503-9. PubMed ID: 15120713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E1 -containing nanoparticles improve walking activity in an experimental rat model of intermittent claudication.
    Ishihara T; Yamashita Y; Takasaki N; Yamamoto S; Hayashi E; Tahara K; Takenaga M; Yamakawa N; Ishihara T; Kasahara T; Mizushima T
    J Pharm Pharmacol; 2013 Aug; 65(8):1187-94. PubMed ID: 23837586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of intravenous administration of lipo-prostaglandin E1 on the ischemic gastric tube in pigs.
    Tobari S; Ikeda Y; Takami H
    J Surg Res; 2005 Nov; 129(1):79-84. PubMed ID: 16087193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1.
    Weiss T; Eckstein H; Weiss C; Diehm C
    Vasc Med; 1998; 3(3):171-5. PubMed ID: 9892509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent intraarterial infusion therapy with PGE1 in patients with severe claudication--results of a randomized prospective double blind study.
    Caspary L; Creutzig A; Radeke U; Specht S; Alexander K
    Biomed Biochim Acta; 1988; 47(10-11):S307-10. PubMed ID: 3073766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication.
    Mangiafico RA; Messina R; Attinà T; Dell'Arte S; Giuliano L; Malatino LS
    Angiology; 2000 Jun; 51(6):441-9. PubMed ID: 10870853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intermittent intra-arterial infusion treatment of severe intermittent claudication. Results of a prospective double-blind study: prostaglandin El versus energy-rich phosphates].
    Creutzig A; Caspary L; Radeke U; Specht S; Ranke C; Alexander K
    Med Klin (Munich); 1988 Jun; 83(13-14):434-8. PubMed ID: 3062344
    [No Abstract]   [Full Text] [Related]  

  • 15. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].
    Luzzi R; Belcaro G; Ippolito E; Dugall M; Cesarone MR; Scoccianti M; Errichi BM; Pellegrini L; Ciammaichella G; Ledda A; Ricci A; Cornelli U; Feragalli B; Hosoi M; Corsi M; Simeone E; Agus GB
    Minerva Cardioangiol; 2012 Aug; 60(4):405-13. PubMed ID: 22858918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
    Bucci M; Iacobitti P; Laurora G; Cesarone MR
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iontophoretic application of prostaglandin E1 for improvement in peripheral microcirculation.
    Saeki S; Yamamura K; Matsushita M; Nishikimi N; Sakurai T; Nimura Y
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):525-9. PubMed ID: 9799055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
    Belcaro G; Laurora G; Nicolaides AN; Agus G; Cesarone MR; DeSanctis MT; Incandela L; Ricci A; Cazaubon M; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Iacobitti P; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Bucci M; Ferrari PG; Corsi M; Pomante P; Mezzanotte L; Geroulakos G
    Angiology; 1998 Nov; 49(11):885-94; discussion 895. PubMed ID: 9822044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial.
    Diehm C; Balzer K; Bisler H; Bulling B; Camci M; Creutzig A; Gruss JD; Horsch S; Odemar F; Piehler U; Rogatti W; Scheffler P; Spengel F; Treese N; Turowski A; Waldhausen P; Weber B; Weiss T
    J Vasc Surg; 1997 Mar; 25(3):537-44. PubMed ID: 9081136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
    Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E
    Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.